The once-daily human Glucagon-Like Peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

Advances in Therapy

Volumn 28, Issue 3, 2011, Pages 213-226

  Flint, Anne ^a   Kapitza, Christoph ^b   Hindsberger, Charlotte ^a   Zdravkovic, Milan ^a  

^a NOVO NORDISK A S   (Denmark)

^b Profil Institut fur Stoffwechselforschung GmbH   (Germany)

Author keywords

Exenatide; Gastric emptying; Incretin; Insulin; Type 2 diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; PARACETAMOL; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DYSPEPSIA; ELECTROCARDIOGRAM; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOGLYCEMIA; INFECTION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STEADY STATE; STOMACH EMPTYING; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 79958094404     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-010-0110-x     Document Type: Article

References (57)

1. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998;19:491-503. (Pubitemid 29116017)
2. Knop FK, Vilsbøll T, Højberg PV, et al. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951-1959.
3. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52. (Pubitemid 16162741)
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412. (Pubitemid 30609442)
6. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881-885. (Pubitemid 36929359)
7. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis. 2008;18:S17-S33.
8. Elrick H, Stimmler L, Hlad CJ, Arai Y. Plasma insulin responce to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076-1082.
9. Creutzfeldt W. The incretin concept today. Diabetologia. 1979;16:75-85. (Pubitemid 9231263)
10. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut. 2006;55:243-251. (Pubitemid 43117285)
11. Delgado-Aros S, Kim D, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol Gastrointest Liver Physiol. 2002;282:G424-G431. (Pubitemid 34651657)
12. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981-E988.
13. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:2719-2725. (Pubitemid 36733545)
14. Meier JJ, Gethmann A, Götze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia. 2006;49:452-458. (Pubitemid 43277867)
15. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab. 2001;86:4382-4389.
16. Schirra J, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans. Gut. 2002;50:341-348.
17. Schirra J, Houck P, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut. 2000;46:622-631.
18. Anvari M, Paterson CA, Daniel EE, McDonald TJ. Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid. Dig Dis Sci. 1998;43:1133-1140. (Pubitemid 28272542)
19. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943-2952.
20. Juhl CB, Hollingdal M, Sturis J, et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002;51:424-429. (Pubitemid 34764798)
21. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301-307. (Pubitemid 23037285)
22. Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab. 1996;81:327-332.
23. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705. (Pubitemid 46048557)
24. Vilsbøll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs. 2007;16:231-237. (Pubitemid 46206637)
25. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002;45:195-202. (Pubitemid 34208381)
26. Nauck M, Hompesch M, Filipczak R, Le T, Zdravkovic M, Gumprecht J. Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes. Exp Clin Endocrinol Diabetes. 2006;114:417-423. (Pubitemid 44620484)
27. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007;30:1608-1610. (Pubitemid 46871185)
28. Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268-278.
29. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84-90.
30. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473-481.
31. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224-1230.
32. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009;52:2046-2055.
33. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
34. WMA General Assembly. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed January 21, 2011.
35. Willems M, Quartero AO, Numans ME. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci. 2001;46:2256-2262. (Pubitemid 32955241)
36. Glerup H, Bluhme H, Villadsen GE, Rasmussen K, Ejskjaer N, Dahlerup JF. Gastric emptying: a comparison of three methods. Scand J Gastroenterol. 2007;42:1182-1186. (Pubitemid 47537091)
37. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993;39:578-582. (Pubitemid 23118305)
38. Le Floch JP, Baudin E, Escuyer P, Wirquin E, Yomtov B, Perlemuter L. Reproducibility of glucose and insulin responses to mixed meal in type II diabetic patients. Diabetes Care. 1991;14:138-140.
39. ADA. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(suppl. 1):S12-S54.
40. Green GM, Guan D, Schwartz JG, Phillips WT. Accelerated gastric emptying of glucose in Zucker type 2 diabetic rats: role in postprandial hyperglycaemia. Diabetologia. 1997;40:136-142. (Pubitemid 27060284)
41. Näslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord. 1999;23:304-311. (Pubitemid 29118862)
42. Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab. 2006;91:1916-1923.
43. Horowitz M, Dent J. Disordered gastric emptying: mechanical basis, assessment and treatment. Baillières Clin Gastroenterol. 1991;5:371-407.
44. Collins PJ, Horowitz M, Cook DJ, Harding PE, Shearman DJ. Gastric emptying in normal subjects - a reproducible technique using a single scintillation camera and computer system. Gut. 1983;24:1117-1125. (Pubitemid 14205812)
45. Jones KL, Russo A, Berry MK, Stevens JE, Wishart JM, Horowitz M. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am J Med. 2002;113:449-455. (Pubitemid 35335795)
46. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia. 1993;36:857-862. (Pubitemid 23248159)
47. Schvarcz E, Palmér M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113:60-66. (Pubitemid 27281758)
48. Spechler SJ, Wan HH, Chey YY. GERD versus H. pylori infections as potential causes of inflammation in the gastric cardia. Gastroenterology. 1997;112:A297.
49. Knudsen LB, Jelsing J, Vrang N, Tang-Christensen M, Raun K. Frequency and magnitude of antibody formation are lower with liraglutide than exenatide: LEAD-6 results. Diabetes. 2010;59:A161. Abstract 591-P.
50. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:3082-3089. (Pubitemid 36877476)
51. Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151:123-129.
52. Bunck MC, Cornér A, Eliasson B, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis. 2010;212:223-229.
53. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30:1487-1493. (Pubitemid 46871159)
54. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabetic Med. 2008;25:152-156. (Pubitemid 351293400)
55. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003;52:380-386. (Pubitemid 36173193)
56. Amylin Pharmaceuticals. Byetta Package insert. 2009. Available at: http://pi.lilly.com/us/byetta-pi.pdf. Accessed January 21, 2011.
57. Novo Nordisk. Victoza® prescribing information. 2010. Available at: http://www.victoza.com/pdf/Victoza-ComboPI-5.24.pdf. Accessed January 21, 2011.